Sickle Cell Treatment Developed At LA BioMed Approved For Phase 3 Clinical Trial
The Food and Drug Administration (FDA) gave its approval this week for Emmaus Medical, Inc. to begin a Phase 3 clinical trial of an experimental treatment for sickle cell disease. The patented experimental treatment was originally developed by investigators led by Yutaka Niihara, MD, MPH, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and is licensed to Emmaus Medical.
More: continued here
Filed under: Blood on April 26th, 2009
You must be logged in to post a comment.